Business
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection
– VOWST is now available by prescription in the U.S. for adult patients following antibiotic treatment for recurrent CDI – – VOWST Voyage™ Support Program to
About this update from Seres Therapeutics, Inc.
[{"type":"text","content":"\n– VOWST is now available by prescription in the U.S. for adult patients following antibiotic treatment for recurrent CDI –\n\n\n– VOWST Voyage™ Support Program to help reduce out-of-pocket patient costs for eligible patients and facilitate treatment start –\n\n\n CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--\nSeres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced that VOWST™ (fecal microbiota spores, live-brpk) is now commercially available for patients. VOWST, formerly called SER-109, is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is not indicated for the treatment of CDI.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230605005120/en/\n“The commercial availability of VOWST provides a new oral dosing option that has demonstrated efficacy in the prevention of further recurrences of rCDI, including those who have experienced a first recurrence. We look forward to helping patients who have this potentially life-threatening disease,” said Eric Shaff, President and Chief Executive Officer at Seres.\n\n\n“At Nestlé Health Science, we are leveraging our strong existing infrastructure, including our gastrointestinal sales force and payer access team, to commercialize VOWST and provide this product to those who need it most,” said Greg Behar, Chief Executive Officer, Nestlé Health Science. “Since the approval of VOWST, our teams have engaged with healthcare professionals and are committed to facilitating patient access.”\n\n\n\"As a treating physician, I am pleased to now have the ability to prescribe VOWST, a 3-day oral regimen, to eligible patients in my practice,” said Carl Crawford M.D., Assistant Professor of Clinical Medicine at Weill Cornell Medical College. “Recurrent C. difficile infection is a challenging and debilitating disease, and VOWST has potential to make a meaningful impact to this patient community.”\n\n\nVOWST Voyage™\nSeres Therapeutics and Nestlé Health Science are committed to broad access for appropriate patients. The VOWST Voyage Support Program offers a range of resources and programs designed to help eligible pat...